Infectous disease header.jpg
Infectious disease thumbnail.jpg

Infectious Disease

Infectious Disease Antibodies from BBI

At BBI Solutions, we offer a diverse range of monoclonal antibodies against an expansive range of infectious disease targets to ensure the reliability and performance of your diagnostic assays. 

BBI Solutions’ infectious disease monoclonal antibodies are renowned as sensitive, cost-efficient products for assay developers, manufacturers and researchers worldwide. They are available in both small and bulk quantities depending on your individual requirements.  Our infectious disease monoclonal antibodies are tested by a variety of methods including ELISA and Lateral Flow, providing recommended matched pairings, saving you time and money. 

With matched pair offerings for important targets such as HIV, Norovirus, Influenza, and many more, trust BBI to provide high quality infectious disease antibodies for your diagnostic assay needs. 

Please contact our Customer Services Team directly to discuss your requirements on tel:+44 (0) 1495 363000 or alternatively you can submit an enquiry here.

Related Products

If you require any further product specific technical information or datasheets please submit your request to our technical team here 

Antibodies FAQs

Our team are here to help! If you can’t find the answer you are looking for contact us.

Antibodies are a critical component of the defense arsenal assisting with identifying, capturing, and removing potential threats as well as protecting against future invasions. Antibodies are gammaglobulin proteins, predominantly referred to as immunoglobulins (Ig). A monomeric antibody is composed of two heavy chains and two light chains covalently linked together through disulfide bonds to generate a Y-shaped structure. This Y-shaped structure provides a bifunctional capacity: 1) antigen-binding through the Fab (antigen binding fragment), and 2) interaction with immune cells and proteins (fragment crystallizable or Fc) to initiate and regulate host defence mechanisms.

Polyclonal antibodies refer to a mixture of immunoglobulin molecules that are secreted against a particular antigen. They interact with different epitopes on the same antigen and their manufacture
does not require the use of hydbridomas. Monoclonal antibodies refer to a homogenous population of antibodies that are produced by a single clone of plasma B cells. They interact with a particular epitope on the antigen and their manufacture requires the use of a hybridoma cell line.

This varies between products, please consult the example Certificate of Analysis for this information.

This varies between products, please consult the example Certificate of Analysis for this information.

Yes, we manufacture many of our own products at our 2 manufacturing sites in Maine, USA and Porton Down, UK. All sites are ISO13485 certified.

BBI Solutions offers a growing portfolio of performance proven antibodies. With our in-house custom antibody expertise, customers can rely on BBI to be a trusted partner in antibody support, from secure
supply, to matched pair recommendations, and trouble shooting performance. Custom manufacturing lots and conjugation services are also value-added services available for most of our antibodies to suit your assay development needs.

A matched antibody pair consists of two antibodies, a capture and a detection antibody. In a matched pair, each antibody is specific for a different and non-interfering epitope of the antigen

Hybridoma.

Rabbit, Goat and Sheep.

Roller bottle for lot sizes up to 1gram. Hollow fibre continuous perfusion system for lot sizes greater than 1 gram.

4-6 months for a monoclonal antibody and 3-4 months for a polyclonal.

discussion with a service team member will be necessary regarding this, however monoclonal development projects start at $20k and up.

Why choose BBI Solutions Infectious Disease Antibodies?

BBI Solutions’ infectious disease monoclonal antibodies are renowned as sensitive, cost-efficient products for assay developers, manufacturers and researchers worldwide. They are available in both small and bulk quantities depending on your individual requirements.  Our infectious disease monoclonal antibodies are tested by a variety of methods including ELISA and Lateral Flow, providing recommended matched pairings, saving you time and money. 

With matched pair offerings for important targets such as HIV, Norovirus, Influenza and many more, trust BBI to provide high quality infectious disease antibodies for your diagnostic assay needs. 

Respiratory Diseases 

  •  Including Influenza, RSV, Mycoplasma pneumoniae, Adenovirus 
  • Matched pairs available 
  • cGMP* manufacture for increased batch-to-batch consistency 

*21 CFR Part 820, For Research and In Vitro Diagnostic Use Only 

Foodborne Pathogens 

  • Campylobacter jejuni, E.coli O157, H.pylori, Listeria, Norovirus, Rotavirus 
  • Comprehensive reactivity profile of 10 Norovirus antibody panel to meet any detection goal 
  • Matched pairs available 

Vector Borne Pathogens 

  • B.burgdorferi, Chikungunya, Dengue, Zika, Rift Valley Fever  
  • Broad vector borne disease range including the emerging Zika virus 

Sexually Transmitted Infectious 

  • HIV 
  • Multiple matched pairs with distinct binding profiles available 
  • Total reagent solution with BBI’s own recombinant HIV-1 p24 antigen 
  • cGMP* manufacture for increased batch-to-batch consistency 

*21 CFR Part 820, For Research and In Vitro Diagnostic Use Only 

Hospital Acquired Infections 

  • C.difficile, Streptococcus A 
  • Matched pairs available 

Request a callback

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox